Pharming Group (PHAR)
(Delayed Data from NSDQ)
$9.80 USD
-0.65 (-6.22%)
Updated Apr 26, 2024 02:34 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
PHAR 9.80 -0.65(-6.22%)
Will PHAR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHAR
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
Other News for PHAR
Pharming Group’s Strategic Financial Maneuver
Pharos Energy Announces AGM and Annual Report
Pharos Energy Announces AGM and Year-end Report
Pharming Group Lauded for Rare Disease Treatment
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards